ROQ vs. IXI, OPTI, FUM, OBD, SNG, BVX, TRX, CIZ, TCF, and GENF
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include IXICO (IXI), OptiBiotix Health (OPTI), Futura Medical (FUM), Oxford BioDynamics (OBD), Synairgen (SNG), BiVictriX Therapeutics (BVX), Tissue Regenix Group (TRX), Cizzle Biotechnology (CIZ), Theracryf (TCF), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs. Its Competitors
IXICO (LON:IXI) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.
12.8% of IXICO shares are held by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are held by institutional investors. 6.0% of IXICO shares are held by company insiders. Comparatively, 20.3% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Roquefort Therapeutics has lower revenue, but higher earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Roquefort Therapeutics' average media sentiment score of 0.21 beat IXICO's score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the news media.
IXICO has a net margin of -31.10% compared to Roquefort Therapeutics' net margin of -57,057.07%. IXICO's return on equity of -19.14% beat Roquefort Therapeutics' return on equity.
IXICO has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.
Summary
IXICO beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ROQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 10/9/2025 by MarketBeat.com Staff
